🟢 97/100

This product looks safe

  • Niacin: 375mg is 10.7× the Tolerable Upper Intake Level (35mg)
  • 38% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 375mg is 10.7× the Tolerable Upper Intake Level (35mg)

Label Data

2 Tablet(s) Serving Size
60 Servings
Other Combinations Product Type
38% Evidence Coverage

Supplement Facts — Evidence Check

Phytosterol Complex
150 mg
375 mg
⚠️ Exceeds Tolerable Upper Intake Level by 10.7× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 375mg UL 35mg
Guar Gum
50 mg
Lecithin
450 mg
📊 Market median: 600.0mg (79 products) 📚 24 studies (Tier A: 0, B: 6)
This product: 175mg
68 mg
✅ Within RDA (0.1× RDA of 550 mg) 📚 36 studies (Tier A: 1, B: 7)
RDA 550mg This product: 68mg UL 3500mg
75 mg
📊 Market median: 550.0mg (217 products) 📚 29 studies (Tier A: 0, B: 5)
This product: 75mg
500 mcg
📊 Market median: 200.0mg (136 products) 📚 3 studies — no high-quality reviews
This product: 0.5mg
Papain
50 mg
📊 Market median: 500.0mg (283 products) 📚 173 studies (Tier A: 0, B: 62)
This product: 50mg
Hesperidin
13 mg
5 mg
📊 Market median: 500.0mg (19 products)
This product: 5mg
Synergistically Balanced Proprietary Blend
150 mg

Other Ingredients

Cellulose Calcium Vegetable Stearate Silica

Label Claims — Verification

No Claim
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

🧪 Formulation Notes

A phytospiritually formulated lab tested product

Additional Information

Health Yourself

Product Details

DSLD Entry Date 2021-01-22
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 243814
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →